Your browser doesn't support javascript.
loading
ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2.
Huebner, Kerstin; Erlenbach-Wuensch, Katharina; Prochazka, Jan; Sheraj, Ilir; Hampel, Chuanpit; Mrazkova, Blanka; Michalcikova, Tereza; Tureckova, Jolana; Iatsiuk, Veronika; Weissmann, Anne; Ferrazzi, Fulvia; Kunze, Philipp; Nalli, Enise; Sammer, Elisabeth; Gehring, Annemarie; Cheema, Marie M; Eckstein, Markus; Paap, Eva-Maria; Soederberg, Agnes; Fischer, Corinna; Paul, Sushmita; Mahadevan, Vijayalakshmi; Ndreshkjana, Benardina; Meier, Melanie A; Muehlich, Susanne; Geppert, Carol I; Merkel, Susanne; Grutzmann, Robert; Roehe, Adriana; Banerjee, Sreeparna; Hartmann, Arndt; Sedlacek, Radislav; Schneider-Stock, Regine.
Afiliação
  • Huebner K; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Erlenbach-Wuensch K; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
  • Prochazka J; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic.
  • Sheraj I; Department of Biological Sciences, Middle East Technical University, 06800, Ankara, Turkey.
  • Hampel C; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Mrazkova B; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic.
  • Michalcikova T; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic.
  • Tureckova J; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic.
  • Iatsiuk V; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic.
  • Weissmann A; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Ferrazzi F; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
  • Kunze P; Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nürnberg, 91054, Erlangen, Germany.
  • Nalli E; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Sammer E; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Gehring A; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Cheema MM; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Eckstein M; Czech Center for Phenogenomics, Institute of Molecular Genetics of the ASCR, v.v.i, 142 20, Prague, Czech Republic.
  • Paap EM; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
  • Soederberg A; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Fischer C; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Paul S; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Mahadevan V; Department of Bioscience and Bioengineering, Indian Institute of Technology Jodhpur, Jodhpur, 342037, India.
  • Ndreshkjana B; Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore, 560100, India.
  • Meier MA; Experimental Tumor Pathology, Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsstraße 22, 91054, Erlangen, Germany.
  • Muehlich S; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich Alexander University Erlangen-Nürnberg, 91058, Erlangen, Germany.
  • Geppert CI; Department of Chemistry and Pharmacy, Molecular and Clinical Pharmacy, Friedrich Alexander University Erlangen-Nürnberg, 91058, Erlangen, Germany.
  • Merkel S; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
  • Grutzmann R; Department of Surgery, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany.
  • Roehe A; Department of Surgery, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany.
  • Banerjee S; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, 91054, Erlangen, Germany.
  • Hartmann A; Department of Pathology and Legal Medicine, Federal University of Health Sciences of Porto Alegre, Porto Alegre, 90050-170, Brazil.
  • Sedlacek R; Department of Biological Sciences, Middle East Technical University, 06800, Ankara, Turkey.
  • Schneider-Stock R; Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
Cell Mol Life Sci ; 79(8): 423, 2022 Jul 15.
Article em En | MEDLINE | ID: mdl-35838828
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Fator 2 Ativador da Transcrição / Antígenos de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cell Mol Life Sci Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Fator 2 Ativador da Transcrição / Antígenos de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cell Mol Life Sci Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha